HF
RLMD icon

HRT Financial’s Relmada Therapeutics RLMD Stock Holding History

HRT Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,162
Closed -$7K – 3534
2025
Q2 		$7K Sell
12,162
-39,881
-77% -$20.5K ﹤0.01% 2473
2025
Q1 		$14K Buy
+52,043
New +$17.3K ﹤0.01% 2329
2023
Q3 		– Sell
-14,840
Closed -$36K – 2987
2023
Q2 		$36K Buy
+14,840
New +$41K ﹤0.01% 2047
2023
Q1 		– Sell
-158,320
Closed -$552K – 3090
2022
Q4 		$552K Buy
+158,320
New +$1.39M 0.01% 1338

Other funds holding RLMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

HRT Financial's RLMD Position: Q3 2025 in Review

HRT Financial sold out of Relmada Therapeutics (RLMD) in Q3 2025, closing a stake of 12,162 shares — an estimated $7K sold.

HRT Financial first reported a position in RLMD in Q4 2022 and held it in 4 quarters. The position peaked at $552K in Q4 2022. 44 funds tracked by Wall St. Rank hold RLMD as of Q3 2025.

  • HRT Financial reported no remaining Relmada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 12,162 Relmada Therapeutics shares in Q3 2025, an estimated $7K.
  • HRT Financial first reported a position in Relmada Therapeutics in Q4 2022 and held it in 4 quarters.
  • HRT Financial's Relmada Therapeutics position peaked at $552K in Q4 2022.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.